Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuromodulation and fampridine to enhance gait rehabilitation in multiple sclerosis with cerebellar ataxia
2014-004650-34Phase 4Active
- Sponsor
- IRCCS Mondino Foundation
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in multiple sclerosis (MS) comparing Fampridine plus rehabilitation-based intervention with Placebo plus rehabilitation-based intervention (2 arms). Primary endpoint: Primary efficacy endpoint. Started Nov 2020; status: active.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-004650-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004650-34.